GT Biopharma Inc (GTBP)

NASDAQ
7.67
-0.38(-4.72%)
After Hours
8.06
+0.39(+5.08%)
- Delayed Data
  • Volume:
    498,240
  • Bid/Ask:
    7.75/8.10
  • Day's Range:
    7.25 - 8.28
  • Type:Equity
  • Market:United States
  • ISIN:US36254L2097
  • CUSIP:00036254L209

GTBP Overview

Prev. Close
8.05
Day's Range
7.25-8.28
Revenue
-
Open
8.05
52 wk Range
2.55-19.73
EPS
-8.88
Volume
498,240
Market Cap
233.8M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
339,983
P/E Ratio
-
Beta
0.37
1-Year Change
165.4%
Shares Outstanding
30,482,193
Next Earnings Date
Nov 18, 2021
What is your sentiment on GT Biopharma Inc?
or
Market is currently closed. Voting is open during market hours.

GT Biopharma Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellSell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

GT Biopharma Inc Company Profile

GT Biopharma Inc Company Profile

Employees
3

GT Biopharma, Inc. is a clinical-stage, biopharmaceutical company. The Company is focused on the development of novel immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The Company's TriKE platform generate therapeutics designed to harness and enhance the cancer killing abilities of a patient's own natural killer (NK) cells. GTB-3550 is the Company's first TriKE product candidate, which is a single-chain, tri-specific recombinant fusion protein construct consisting of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The Company is focused on studying this anti-CD16-IL-15-anti-CD33 TriKE in CD33 positive leukemias, a marker expressed on tumor cells in acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS) and other hematopoietic malignancies.

Read More
  • wait for nasdaq....or phase 1....well
    0
    • Any thought on this
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.